Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.04 -1.0%	$5.85	$4.35 ▼ $12.38	$303.63M	0.43	210,229 shs	296,962 shs
PRTA Prothena	$5.72 -0.5%	$7.06	$4.32 ▼ $25.42	$307.91M	-0.07	752,503 shs	3.57 million shs
RCKT Rocket Pharmaceuticals	$2.70 -4.6%	$5.31	$2.19 ▼ $26.98	$288.33M	0.69	2.11 million shs	7.23 million shs
SRZN Surrozen	$9.99 +0.9%	$8.97	$5.90 ▼ $18.17	$85.51M	0.58	21,634 shs	126,142 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	0.00%	-5.92%	+2.55%	-13.71%	-16.11%
PRTA Prothena	0.00%	+12.60%	-13.07%	-57.12%	-73.37%
RCKT Rocket Pharmaceuticals	0.00%	-7.85%	-56.94%	-69.07%	-87.99%
SRZN Surrozen	0.00%	+5.38%	+25.50%	-16.75%	+3.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AURA Aura Biosciences	1.6039 of 5 stars	3.6	1.0	0.0	0.0	3.3	0.0
PRTA Prothena	3.5841 of 5 stars	4.2	4.0	0.0	1.8	1.7	1.3
RCKT Rocket Pharmaceuticals	4.9197 of 5 stars	4.2	4.0	4.7	2.2	5.0	1.3
SRZN Surrozen	2.7441 of 5 stars	3.5	3.0	0.0	0.6	5.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	3.25	Buy	$22.00	264.24% Upside
PRTA Prothena	2.33	Hold	$31.50	450.70% Upside
RCKT Rocket Pharmaceuticals	2.41	Hold	$18.60	588.89% Upside
SRZN Surrozen	3.00	Buy	$38.50	285.39% Upside

Current Analyst Ratings Breakdown

Latest SRZN, AURA, RCKT, and PRTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
6/17/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/28/2025	PRTA Prothena	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
PRTA Prothena	$135.16M	2.28	N/A	N/A	$9.05 per share	0.63
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.08 per share	N/A
SRZN Surrozen	$10.65M	8.03	N/A	N/A	($6.55) per share	-1.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-58.63%	-49.74%	8/14/2025 (Estimated)
PRTA Prothena	-$122.31M	-$2.08	N/A	N/A	N/A	-79.94%	-21.61%	-19.32%	8/6/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.63	N/A	N/A	N/A	N/A	-64.92%	-56.13%	8/4/2025 (Estimated)
SRZN Surrozen	-$63.56M	-$24.96	N/A	N/A	N/A	N/A	-842.90%	-71.32%	8/11/2025 (Estimated)

Latest SRZN, AURA, RCKT, and PRTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/9/2025	Q1 2025	SRZN Surrozen	-$1.09	-$3.13	-$2.04	-$7.43	N/A	$0.98 million
5/8/2025	Q1 2025	PRTA Prothena	-$0.92	-$1.12	-$0.20	-$1.12	$8.18 million	$2.83 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A
3/31/2025	Q4 2024	SRZN Surrozen	-$2.54	-$9.10	-$6.56	-$9.10	N/A	$0.66 million
3/24/2025	Q4 2024	AURA Aura Biosciences	-$0.43	-$0.52	-$0.09	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	11.06	11.06
PRTA Prothena	N/A	9.00	9.00
RCKT Rocket Pharmaceuticals	0.05	9.19	9.19
SRZN Surrozen	N/A	10.02	10.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
PRTA Prothena	97.08%
RCKT Rocket Pharmaceuticals	98.39%
SRZN Surrozen	66.57%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	5.40%
PRTA Prothena	9.20%
RCKT Rocket Pharmaceuticals	24.76%
SRZN Surrozen	43.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	50.27 million	47.55 million	Not Optionable
PRTA Prothena	130	53.83 million	48.88 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	80.35 million	Optionable
SRZN Surrozen	80	8.56 million	4.84 million	Not Optionable

SRZN, AURA, RCKT, and PRTA Headlines

Recent News About These Companies

Surrozen, Inc. (NASDAQ:SRZN) Short Interest Down 16.0% in May

June 3, 2025 | marketbeat.com

Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround

May 16, 2025 | zacks.com

Surrozen secures patent for tissue repair technology

May 15, 2025 | investing.com

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

May 14, 2025 | globenewswire.com

Surrozen, Inc.: Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 10, 2025 | finanznachrichten.de

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025 | globenewswire.com

Surrozen files to sell 5.21M shares of common stock for holders

April 25, 2025 | markets.businessinsider.com

Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year

April 2, 2025 | markets.businessinsider.com

Insiders Are Loving These 5 Tech and Biotech Stocks

April 2, 2025 | 247wallst.com

Surrozen Focuses on Ophthalmology Amid Financial Challenges

April 2, 2025 | tipranks.com

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

March 31, 2025 | globenewswire.com

Surrozen, Inc. (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Purchases 1,034,482 Shares

March 29, 2025 | insidertrades.com

Surrozen to focus Wnt expertise, technologies on ophthalmology programs

March 27, 2025 | markets.businessinsider.com

Surrozen to discontinue development of SZN-043 in alcohol associated hepatitis

March 26, 2025 | markets.businessinsider.com

Surrozen, Inc. Prioritizes Ophthalmology Pipeline with $175 Million Financing and Discontinues SZN-043 Development

March 24, 2025 | quiverquant.com

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

March 24, 2025 | globenewswire.com

Surrozen (NASDAQ:SRZN) Stock Quotes, Forecast and News Summary

January 30, 2025 | benzinga.com

HC Wainwright & Co. Initiates Coverage of Surrozen (SRZN) with Buy Recommendation

January 30, 2025 | msn.com

H.C. Wainwright sets $32 target on Surrozen stock with Buy rating

January 30, 2025 | msn.com

(SRZN) Trading Advice

January 30, 2025 | news.stocktradersdaily.com

Surrozen initiated with a Buy at H.C. Wainwright

January 30, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN, AURA, RCKT, and PRTA Company Descriptions

Aura Biosciences NASDAQ:AURA

$6.04 -0.06 (-0.98%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$6.02 -0.01 (-0.25%)

As of 06/20/2025 06:07 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Prothena NASDAQ:PRTA

$5.72 -0.03 (-0.52%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$5.83 +0.11 (+1.91%)

As of 06/20/2025 07:46 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.70 -0.13 (-4.59%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.72 +0.02 (+0.74%)

As of 06/20/2025 07:59 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Surrozen NASDAQ:SRZN

$9.99 +0.09 (+0.91%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$10.00 +0.01 (+0.10%)

As of 06/20/2025 04:11 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time